Compare Nasdaq Inc (NDAQ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Novo Nordisk A/S — how do they compare? Nasdaq Inc trades at $94.62 (market cap $53.13B), while Novo Nordisk A/S trades at $44.78 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 3.8× Nasdaq Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NDAQ | NVO | |
|---|---|---|
Market Cap | $53.13B | $200.69B |
Sector | Financials | Health |
52-Week High | $100.98 | $63.98 |
52-Week Low | $76.85 | $35.29 |
Enterprise Value | $59.58B | $215.49B |
Dividend Yield | 1.22% | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, up from $7.4B in 2024, and net income margin improved to 22.52%. Recent news highlights Nasdaq's acquisition of Dasseti to enhance AI capabilities in investment technology.
The outlook for NDAQ is positive, supported by consistent earnings outperformance, revenue growth, and strategic acquisitions. Risks include market volatility and competitive pressures. Analysts maintain a bullish consensus with a $109.20 price target, implying 15% upside from current levels.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
